Teva settles in Israel on bribes
Teva has struck a settlement deal with Israeli authorities to end an investigation into “improper payments” relating to the firm’s operations in Mexico, Russia and Ukraine. The investigation related to activities – including bribing government officials – that ended in 2012 and over which Teva agreed a US$519 million US settlement more than a year ago (Generics bulletin, 6 January 2017, page 3).
You may also be interested in...
Viatris’ Mylan has accused Teva of creating a perfect ‘playbook’ to delay Mylan’s launch of a generic version of its Copaxone blockbuster and then strangle uptake, something Mylan was vocal about years earlier, in a suit filed in a New Jersey court.
The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.
Clear progress is being made in the European value added medicines sector, Medicines for Europe’s outgoing sector chair Arun Narayan has highlighted in an interview with Generics Bulletin. However, there is still more work to be done to ensure that the market is supported by imminent legislative and regulatory initiatives.